Boston Scientific Scimed, Inc.

Boston Scientific Medical Device Limited

Nextern Innovation, LLC

Other

Baylis Medical Company Inc.

Pedersen, Wesley Robert

Sorajja, Paul

Paul Sorajja

Wesley Robert Pedersen

Joseph T Delaney, Jr

Douglas Dean Pagoria

Douglas Pennington

William Joseph Drasler

Joel T Eggert

Sarah Melissa Gruba

Tatyana Dyndikova

Andrew J Ro

Richard Lee Tadsen

A transseptal system can include a guidewire, a dilator, and a deflectable sheath configured to safely deliver a puncture needle through a septal wall associated with the fossa ovalis and into a central region of the left atrium of a heart. The dilator can include a dilator nose having a first outer diameter and a dilator beveled segment, extending proximal of the dilator nose, tapering from a second, greater outer diameter to the first outer diameter. The length and interplay of the puncture needle and the dilator nose can be configured such that the puncture needle is inhibited from bending and impinging upon the left side of the atrial septum of the heart during use. A body of the guidewire can include at least one loop segment to provide stable support in the left atrium for delivery of a diagnostic or therapeutic device along its more proximal portions. The deflectable sheath can position and align the dilator nose relative to the fossa ovalis.

Transseptal systems, devices and methods

A temporary pacing lead has an atraumatic curled distal region with multiple cathodes and distal pressure measurement to allow positioning and repositioning within the heart chamber without fluoroscopic or echo guidance. The curled distal region provides definite contact with two opposing walls of the ventricular chamber to ensure electrical signal capture without trauma to the endocardial surface. A stylet located in the pacing lead lumen assists in introducing, placing, and removing the pacing lead from the heart. The flexible distal region provides safe removal of the temporary lead following completion of use.

Temporary pacing lead

A trans-atrial septal catheter system for delivery of a steerable sheath into the left atrium contains three components. The first component is a three-segmented needle-guide wire composed of a distal needle designed to flex sharply in relation to the conjoined looped guide wire segment after fossa ovalis puncture and needle advancement. The distal guide wire loops are advanced into the left atrium maintaining the angled needle in a central location relevant to the loops for preserving an atraumatic position while stabilizing the loops in the left atrium. The elongated proximal extra stiff guide wire segment is conjoined to the looped segment which crosses the fossa ovalis and extends proximally to become externalized to the femoral vein. This segment is extra stiff and significantly elongated to permit catheter and device exchanges. The guide wire serves as a support rail over which the dilator and sheath can be advanced into the left atrium. This transseptal system is uniquely forward looking and permits cautious and iterative delivery of the dilator into the fossa ovalis for 'tenting' by way of a proximal sheath activator that interacts with the dilator. The proximal externalized GW is then advanced to permit puncture of the fossa ovalis. After puncturing a precise location of the fossa ovalis, the needle and coiled guide wire loops are further advanced into the left atrium. With the proximal activator, the dilator is advanced across the fossa ovalis into the left atrium using single-handed maneuvering for separate dilator advancement and steering of the sheath by way of turning or actuating the sheath handle.

Transseptal guide wire puncture system

A functional gadolinium contrast agent comprising a gadolinium cation and a ligand secured to the gadolinium cation is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing gadolinium contrast agents from a patient is disclosed, the method comprising providing a gadolinium contrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the gadolinium contrast agent to the patient; conducting a magnetic resonance imaging procedure; and sequestering the gadolinium contrast agent on the capture substrate. A system for removing gadolinium contrast agents is also disclosed.

Gadolinium contrast agents, scavenging methods, and scavenging system

An imaging contrast composition comprising an iodinated contrast agent and a ligand secured to the iodinated contrast agent is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing iodinated radiocontrast agents from a patient is disclosed, the method comprising providing an iodinated radiocontrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the iodinated radiocontrast agent to the patient; conducting procedure CT scan or procedure using fluoroscopy; and sequestering the iodinated radiocontrast agent on the capture substrate.

Radiocontrast agents, scavenging methods, and scavenging system

Growing community of inventors

Minneapolis, MN, United States of America

Paul Sorajja